Evidence map›Paper›PMID 37326394›Full record

ArticleActa medica academica2023

P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma.

Athanasios Niotis, Evangelos Tsiambas, Dimitrios Dimitroulis, Helen Sarlanis, Evangelos Falidas, Nikolaos Kavantzas, Constantinos A Constantinides

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta medica academica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Athanasios NiotisSecond Department of Propedeutic Surgery, 'Laiko' General Hospital, Medical School, National and Kapodistrian University, Athens, Greece. athanasiosniotis@gmail.com.
Evangelos TsiambasDepartment of Cytology, 417 Veterans Army Hospital (NIMTS), Athens, Greece; Department of Pathology, Medical School, National and Kapodistrian University, Athens, Greece.
Dimitrios DimitroulisSecond Department of Propedeutic Surgery, 'Laiko' General Hospital, Medical School, National and Kapodistrian University, Athens, Greece.
Helen SarlanisDepartment of Pathology, Medical School, National and Kapodistrian University, Athens, Greece.
Evangelos FalidasDepartment of Surgery, Halkida General Hospital, Halkida, Greece.
Nikolaos KavantzasDepartment of Pathology, Medical School, National and Kapodistrian University, Athens, Greece.
Constantinos A ConstantinidesDepartment of Urology, Medical School, National and Kapodistrian University, Athens, Greece.
National and Kapodistrian University of Athens · GRLaiko General Hospital of Athens · GRKAT General Hospital of Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current molecular review, we describe the mechanisms of TP53/MDM2 deregulation and their impact on the colon adenocarcinoma molecular substrate and phenotype. Among the genes that are critically altered in carcinogenesis, the TP53 tumor suppressor gene is of major importance. The TP53 gene (gene locus: 17p13.1) regulates the cell cycle by controlling the G1/S and G2/M checkpoints securing the normal sequence of cell cycle phases. Furthermore, it is involved in apoptosis programmed cell death. The gene is mutated or epigenetically altered in all epithelial malignancies, including colon adenocarcinoma. Additionally, Mouse Double Minute 2 Homolog (MDM2), a proto-oncogene (12q14.3), acts as a major negative regulator for p53 expression in the p53-MDM2 auto-regulatory pathway. MDM2 binds directly to p53 and represses its transcriptional activity, promoting p53 degradation.

conclusionIn colon adenocarcinoma, MDM2 oncogene overexpression directly influences p53 oncoprotein expression levels.

Indexed as

AdenocarcinomaColonic NeoplasmsAnimalsGenes, p53HumansMiceProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53MDM2 protein, humanProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53CarcinomaColonGeneticsImmunohistochemistryp53-MDM2

Identifiers

PMID37326394
PMCPMC10316079
OpenAlexW4380632835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.